Recombinant CCR2 (Plozalizumab Biosimilar) antibody
The Mammalian Cells Monoclonal anti-CCR2 (Plozalizumab Biosimilar) antibody is suitable to detect CCR2 (Plozalizumab Biosimilar) in samples from Human. It has been validated for ELISA.
Catalog No. ABIN7488078
$323.13
Plus shipping costs $50.00
Shipping to:
United States
Delivery in 7 to 10 Business Days
Quick Overview for Recombinant CCR2 (Plozalizumab Biosimilar) antibody (ABIN7488078)
Target
CCR2 (Plozalizumab Biosimilar)
Antibody Type
Recombinant Antibody
Reactivity
Human
Host
Mammalian Cells
Clonality
Monoclonal
Conjugate
This CCR2 (Plozalizumab Biosimilar) antibody is un-conjugated
Application
ELISA
Grade
Research Grade
-
-
Expression System
- Mammalian cells
-
Purpose
- Plozalizumab Biosimilar - Anti-CCR2, CD192 mAb
-
Characteristics
- Antibody Type: IgG1-kappa
-
Purification
- Recombinant antibody expressed in mammalien cells and purified.
-
Isotype
- IgG1 kappa
-
-
-
-
Restrictions
- For Research Use only
-
-
-
Buffer
- PBS pH 7.5
-
Storage
- -80 °C
-
Storage Comment
- store at -80°C
-
-
- CCR2 (Plozalizumab Biosimilar)
-
Target Type
- Biosimilar
-
Background
-
MLN-1202,anti-CCR2,hu1D9
Plozalizumab is a humanized monoclonal antibody that targets CCR2 chemokine receptors found on the surface of white blood cells such as macrophages and monocytes. Plozalizumab has been investigated to treat Atherosclerosis. CCR2 is supposed to play an important role in the trafficking of monocytes and macrophages to sites of inflammation. -
CAS-No
- 1610761-46-0
Target
-
You are here:
